Mirabegron clinical trials

A Phase 3, Open Label, Multicenter, Baseline-controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron Prolonged-release Microgranula-based Suspension in Children from 6 Months to Less Than 3 Years of Age with Neurogenic Detrusor Overactivity

This study is looking at a new way to treat bladder problems in very young children (6 months to under 3 years old) with a condition called neurogenic detrusor overactivity. It's testing a medicine called Mirabegron to see how well it works and if it's safe.